Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination

Alessandra Buoninfante; Arno Andeweg; Alexander T. Baker; Mitesh Borad; Nigel Crawford; Jean Michel Dogné; David Garcia-Azorin; Andreas Greinacher; Rita Helfand; Anders Hviid; Stefan Kochanek; Marta López-Fauqued; Ishac Nazy; Anand Padmanabhan; Sue Pavord; Daniel Prieto-Alhambra; Huyen Tran; Ulla Wandel Liminga; Marco Cavaleri

doi:10.1038/s41541-022-00569-8

Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination

Alessandra Buoninfante, Arno Andeweg, Alexander T. Baker, Mitesh Borad, Nigel Crawford, Jean Michel Dogné, David Garcia-Azorin, Andreas Greinacher, Rita Helfand, Anders Hviid, Stefan Kochanek, Marta López-Fauqued, Ishac Nazy, Anand Padmanabhan, Sue Pavord, Daniel Prieto-Alhambra, Huyen Tran, Ulla Wandel Liminga, Marco Cavaleri

Hematology/Oncology

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Article number	141
Journal	npj Vaccines
Volume	7
Issue number	1
DOIs	https://doi.org/10.1038/s41541-022-00569-8
State	Published - Dec 2022

ASJC Scopus subject areas

Immunology
Pharmacology
Infectious Diseases
Pharmacology (medical)

Access to Document

10.1038/s41541-022-00569-8

Cite this

Buoninfante, A., Andeweg, A., Baker, A. T., Borad, M., Crawford, N., Dogné, J. M., Garcia-Azorin, D., Greinacher, A., Helfand, R., Hviid, A., Kochanek, S., López-Fauqued, M., Nazy, I., Padmanabhan, A., Pavord, S., Prieto-Alhambra, D., Tran, H., Wandel Liminga, U., & Cavaleri, M. (2022). Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination. npj Vaccines, 7(1), [141]. https://doi.org/10.1038/s41541-022-00569-8

Buoninfante, A, Andeweg, A, Baker, AT, Borad, M, Crawford, N, Dogné, JM, Garcia-Azorin, D, Greinacher, A, Helfand, R, Hviid, A, Kochanek, S, López-Fauqued, M, Nazy, I, Padmanabhan, A, Pavord, S, Prieto-Alhambra, D, Tran, H, Wandel Liminga, U & Cavaleri, M 2022, 'Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination', npj Vaccines, vol. 7, no. 1, 141. https://doi.org/10.1038/s41541-022-00569-8

@article{353f2a73a3e540b2a20f3ee96799e908,

title = "Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination",

author = "Alessandra Buoninfante and Arno Andeweg and Baker, {Alexander T.} and Mitesh Borad and Nigel Crawford and Dogn{\'e}, {Jean Michel} and David Garcia-Azorin and Andreas Greinacher and Rita Helfand and Anders Hviid and Stefan Kochanek and Marta L{\'o}pez-Fauqued and Ishac Nazy and Anand Padmanabhan and Sue Pavord and Daniel Prieto-Alhambra and Huyen Tran and {Wandel Liminga}, Ulla and Marco Cavaleri",

note = "Funding Information: We would like to thank all workshop participants for sharing their expertise and insights on the topic of TTS and VITT including the workshop presenters: Nicolas Praet, Kerstin Luhn, Nadia Foskett, and Taylor Cohen, who shared data on behalf of the marketing authorization holders for adenovirus vector COVID-19 vaccines. Funding Information: M.B. declared a research grant to institution from AstraZeneca for clinical study. A.P. reported pending/issued patents in the area of anti-PF4 antibodies, HIT, VITT and platelet storage (assigned to Mayo Clinic, Retham Technologies, and Versiti Blood Center of Wisconsin), equity ownership in and serving as an officer of Retham Technologies, and member of the advisory board of Veralox Therapeutics. D.P.A. receives funding from the UK National Institute for Health and Care Research (NIHR) in the form of a senior research fellowship and from the Oxford NIHR Biomedical Research Centre. His research group has received funding from the European Medicines Agency and Innovative Medicines Initiative. His research group has received research grant/s from Amgen, Chiesi-Taylor, GSK, Novartis, and UCB Biopharma. His department has also received advisory or consultancy fees from Amgen, Astellas, Astra Zeneca, Johnson and Johnson, and UCB Biopharma; and speaker fees from Amgen and UCB Biopharma. Janssen and Synapse Management Partners have supported training programmes organised by DPA{\textquoteright}s department and open for external participants organized by his department outside the submitted work. AG has received funding from the European Medicines Agency and reports consulting fees from: Aspen, Bayer Vital, Chromatec, Instrumentation Laboratory, Macopharma, Sanofi-Aventis, Roche, GTH e.V., Mylan Germany, Takeda Pharma, Falk Foundation e.V., Dilaflor, outside of this work. Also, AG has a patent Screening Methods for transfusion related acute lung injury (TRALI) with royalties paid to EP2321644, 18.05.2011. All the other authors declared no competing interests. ",

year = "2022",

month = dec,

doi = "10.1038/s41541-022-00569-8",

language = "English (US)",

volume = "7",

journal = "npj Vaccines",

issn = "2059-0105",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination

AU - Buoninfante, Alessandra

AU - Andeweg, Arno

AU - Baker, Alexander T.

AU - Borad, Mitesh

AU - Crawford, Nigel

AU - Dogné, Jean Michel

AU - Garcia-Azorin, David

AU - Greinacher, Andreas

AU - Helfand, Rita

AU - Hviid, Anders

AU - Kochanek, Stefan

AU - López-Fauqued, Marta

AU - Nazy, Ishac

AU - Padmanabhan, Anand

AU - Pavord, Sue

AU - Prieto-Alhambra, Daniel

AU - Tran, Huyen

AU - Wandel Liminga, Ulla

AU - Cavaleri, Marco

N1 - Funding Information: We would like to thank all workshop participants for sharing their expertise and insights on the topic of TTS and VITT including the workshop presenters: Nicolas Praet, Kerstin Luhn, Nadia Foskett, and Taylor Cohen, who shared data on behalf of the marketing authorization holders for adenovirus vector COVID-19 vaccines. Funding Information: M.B. declared a research grant to institution from AstraZeneca for clinical study. A.P. reported pending/issued patents in the area of anti-PF4 antibodies, HIT, VITT and platelet storage (assigned to Mayo Clinic, Retham Technologies, and Versiti Blood Center of Wisconsin), equity ownership in and serving as an officer of Retham Technologies, and member of the advisory board of Veralox Therapeutics. D.P.A. receives funding from the UK National Institute for Health and Care Research (NIHR) in the form of a senior research fellowship and from the Oxford NIHR Biomedical Research Centre. His research group has received funding from the European Medicines Agency and Innovative Medicines Initiative. His research group has received research grant/s from Amgen, Chiesi-Taylor, GSK, Novartis, and UCB Biopharma. His department has also received advisory or consultancy fees from Amgen, Astellas, Astra Zeneca, Johnson and Johnson, and UCB Biopharma; and speaker fees from Amgen and UCB Biopharma. Janssen and Synapse Management Partners have supported training programmes organised by DPA’s department and open for external participants organized by his department outside the submitted work. AG has received funding from the European Medicines Agency and reports consulting fees from: Aspen, Bayer Vital, Chromatec, Instrumentation Laboratory, Macopharma, Sanofi-Aventis, Roche, GTH e.V., Mylan Germany, Takeda Pharma, Falk Foundation e.V., Dilaflor, outside of this work. Also, AG has a patent Screening Methods for transfusion related acute lung injury (TRALI) with royalties paid to EP2321644, 18.05.2011. All the other authors declared no competing interests.

PY - 2022/12

Y1 - 2022/12

UR - http://www.scopus.com/inward/record.url?scp=85141608934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85141608934&partnerID=8YFLogxK

U2 - 10.1038/s41541-022-00569-8

DO - 10.1038/s41541-022-00569-8

M3 - Article

AN - SCOPUS:85141608934

SN - 2059-0105

VL - 7

JO - npj Vaccines

JF - npj Vaccines

IS - 1

M1 - 141

ER -

Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this